Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case

Introduction. Cutaneous melanoma is a highly aggressive malignancy with a significant risk of metastasis. Current treatment strategies include surgical resection, immunotherapy, and targeted therapy directed at mutations in the MAPK/ ERK pathway, particularly BRAF V600E. Despite the efficacy of dual...

Full description

Saved in:
Bibliographic Details
Main Authors: V. E. Askarov, A. V. Sultanbaev, K. V. Menshikov, V. S. Chalov, N. I. Sultanbaeva, I. A. Menshikova
Format: Article
Language:English
Published: Bashkir State Medical University 2025-07-01
Series:Креативная хирургия и онкология
Subjects:
melanoma
atezolizumab
vemurafenib
cobimetinib
immunotherapy
tumor biomarkers
sox transcription factors
targeted therapy
Online Access:https://www.surgonco.ru/jour/article/view/1089
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.surgonco.ru/jour/article/view/1089

Similar Items